Condition
HER2 Low Breast Cancer
Total Trials
4
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 1 (3)
P 2 (1)
Trial Status
Recruiting2
Withdrawn1
Not Yet Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT05514717Phase 1Recruiting
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
NCT05868226Phase 1Recruiting
PRE-I-SPY Phase I/Ib Oncology Platform Program
NCT06733233Phase 2Not Yet Recruiting
A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer
NCT04602117Phase 1Withdrawn
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
Showing all 4 trials